Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity

Fertility and Sterility

Volumn 73, Issue 1, 2000, Pages 150-156

  Mather, Kieren J ^a   Kwan, Flora ^a   Corenblum, Bernard ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cardiovascular risk; Insulin resistance; Obesity; Polycystic ovary syndrome

Indexed keywords

INSULIN; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OUTPATIENT DEPARTMENT; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; UNIVERSITY HOSPITAL;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TRIGLYCERIDES;

EID: 0033962541     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00468-9     Document Type: Article

References (36)

1. Franks S. Polycystic ovary syndrome. [review] N Engl J Med. 333:1995;853-859.
2. Goudas V.T., Dumesic D.A. Polycystic ovary syndrome. [review] Endocrinol Metab Clin North Am. 26:1997;893-912.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis . [review] Endocr Rev. 18:1997;774-800.
4. Nestler J.E. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. [review] Semin Reprod Endocrinol. 15:1997;111-122.
5. Nestler J.E. Insulin regulation of human ovarian androgens. [review] Hum Reprod. 12:(Suppl 1):1997;53-62.
6. Willis D., Mason H., Gilling-Smith C., Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 81:1996;302-309.
7. Dunaif A., Segal K.R., Shelley D.R., Green G., Dobrjansky A., Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 41:1992;1257-1266.
8. Dunaif A., Finegood D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;942-947.
9. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 71:1992;599-604.
10. Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 15:1995;821-826.
11. Guzick D.S. Cardiovascular risk in women with polycystic ovarian syndrome. [review] Semin Reprod Endocrinol. 14:1996;45-49.
12. Conway G.S., Agrawal R., Betteridge D.J., Jacobs H.S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol. 37:1992;119-125.
13. Rexrode K.M., Carey V.J., Hennekens C.H., Walters E.E., Colditz G.A., Stampfer M.J., et al. Abdominal adiposity and coronary heart disease in women. JAMA. 280:1998;1843-1848.
14. Wilson P.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
15. American Diabetes Association. Screening for type 2 diabetes (position paper). Diabetes Care 1999;22(Suppl 1):S20-3.
16. Kahn R. Consensus development conference on insulin resistance (American Diabetes Association). Diabetes Care. 21:1998;310-314.
17. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 83:1998;2694-2698.
18. Pierpoint T., McKeigue P.M., Isaacs A.J., Wild S.H., Jacobs H.S. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol. 51:1998;581-586.
19. Birdsall M.A., Farquhar C.M., White H.D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 126:1997;32-35.
20. Prelevic G.M., Beljic T., Balint-Peric L., Ginsburg J. Cardiac flow velocity in women with the polycystic ovary syndrome. Clin Endocrinol. 43:1995;677-681.
21. Guzick D.S., Talbott E.O., Sutton-Tyrrell K., Herzog H.C., Kuller L.H., Wolfson S.K. Carotid atherosclerosis in women with polycystic ovary syndrome initial results from a case-control study . Am J Obstet Gynecol. 174:1996;1224-1229.
22. Paradisi G, Steinberg HO, Shepard M, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. [abstract]. Diabetes 1998;47(Suppl 1):A309.
23. Vidal-Puig A., Munoz-Torres M., Jodar-Gimeno E., Garcia-Calvente C., Lardelli P., Ruiz-Requena M.E., et al. Hyperinsulinemia in polycystic ovary syndrome relationship to clinical and hormonal factors . Clin Investig. 72:1994;853-857.
24. Wild R.A. Metabolic aspects of polycystic ovary syndrome. [review] Semin Reprod Endocrinol. 15:1997;105-110.
25. Graf M.J., Richards C.J., Brown V., Meissner L., Dunaif A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol. 33:1990;119-131.
26. Slowinska-Srzednicka J., Zgliczynski S., Wierzbicki M., Srzednicki M., Stopinska-Gluszak U., Zgliczynski W., et al. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest. 14:1991;569-575.
27. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 22:1999;141-146.
28. Campbell P., Gerich J. Impact of obesity on insulin action in volunteers with normal glucose tolerance demonstration of a threshold for the adverse effect of obesity . J Clin Endocrinol Metab. 70:1990;1114-1118.
29. Rittmaster R.S., Deshwal N., Lehman L. The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab. 76:1993;1295-1300.
30. Dunaif A., Segal K.R., Futterweit W., Drobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174.
31. Garg A. Dyslipoproteinemia and diabetes. [review] Endocrinol Metab Clin North Am. 27:1998;613-625.
32. Toscano V., Bianchi P., Balducci R., Guglielmi R., Mangiantini A., Lubrano C., et al. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism. Clin Endocrinol. 36:1992;197-202.
33. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. [review] Am J Med 1995;98:27S-32S.
34. Ciampelli M., Fulghesu A.M., Cucinelli F., Pavone V., Ronsisvalle E., Guido M., et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 48:1999;167-172.
35. Parra A., Ramirez A., Espinosa M. Fasting glucose/insulin ratio. An index to differentiate normo from hyperinsulinemic women with polycystic ovary syndrome. Revista de Investigacion Clinica. 46:1994;363-368.
36. Ruige J.B., Assendelft W.J.J., Dekker J.M., Kostense P.J., Heine R.J., Bouter L.M. Insulin and risk of cardiovascular disease - a meta-analysis. Circulation. 97:1998;996-1001.